224 research outputs found
myositis an evolving spectrum of disease
AbstractThe idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of disorders characterized, as common feature, by inflammation of skeletal muscle and muscle weakness. Traditionally,..
Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents.
BACKGROUND: Polymyositis (PM) and dermatomyositis (DM) are autoimmune muscle diseases, conventionally treated with high doses of glucocorticoids in combination with immunosuppressive drugs. Treatment is often dissatisfying, with persisting muscle impairment. We aimed to investigate molecular mechanisms that might contribute to the persisting muscle impairment despite immunosuppressive treatment in adult patients with PM or DM using gene expression profiling of repeated muscle biopsies.
METHODS: Paired skeletal muscle biopsies from six newly diagnosed adult patients with DM or PM taken before and after conventional immunosuppressive treatment were examined by gene expression microarray analysis. Selected genes that displayed changes in expression were analyzed by Western blot. Muscle biopsy sections were evaluated for inflammation, T lymphocytes (CD3), macrophages (CD68), major histocompatibility complex (MHC) class I expression and fiber type composition.
RESULTS: After treatment, genes related to immune response and inflammation, including inflammasome pathways and interferon, were downregulated. This was confirmed at the protein level for AIM-2 and caspase-1 in the inflammasome pathway. Changes in genes involved in muscle tissue remodeling suggested a negative effect on muscle regeneration and growth. Gene markers for fast type II fibers were upregulated and fiber composition was switched towards type II fibers in response to treatment. The expression of genes involved in lipid metabolism was altered, suggesting a potential lipotoxic effect on muscles of the immunosuppressive treatment.
CONCLUSION: The anti-inflammatory effect of immunosuppressive treatment was combined with negative effects on genes involved in muscle tissue remodeling and lipid metabolism, suggesting a negative effect on recovery of muscle performance which may contribute to persisting muscle impairment in adult patients with DM and PM
Dysfunction of endothelial progenitor cells is associated with the type I IFN pathway in patients with polymyositis and dermatomyositis
Objective. Alterations in phenotype and function of endothelial progenitor cells (EPCs) have been associated with poor vascular outcomes and impaired vascular repair in various conditions. Our hypothesis was that patients with PM and DM have dysregulation of EPCs driven by type I IFN and IL-18 similar to other autoimmune diseases. Methods. Quantification of circulating EPCs was performed by flow cytometry in patients with PM/DM and matched healthy controls. The ability of EPCs to differentiate into mature endothelial cells was investigated by light and fluorescence microscopy quantification in the presence or absence of PM/DM or control serum, neutralizing antibodies to type I IFN receptor or IL-18. Serum type I IFN activity was quantified by induction of type I IFN-inducible genes in HeLa cells. Circulating IL-18 concentrations were assessed by ELISA. Results. Circulating EPCs were significantly lower in PM/DM patients compared with controls. PM/DM EPCs displayed a decreased capacity to differentiate into mature endothelial cells and PM/DM serum significantly inhibited differentiation of control EPCs. This effect was reversed in the majority of samples with neutralizing antibodies to IL-18 or to type I IFN receptor or by a combination of these antibodies. Patients with associated impairments in EPC function had higher type I IFN serum activity. Conclusion. PM/DM is associated with dysregulation of EPC phenotype and function that may be attributed, at least in part, to aberrant IL-18 and type I IFN pathways. The implication of these vasculopathic findings for disease prognosis and complications remains to be determined
Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease.
OBJECTIVES: To study muscle biopsy tissue from patients with juvenile dermatomyositis (JDM) in order to test the reliability of a score tool designed to quantify the severity of histological abnormalities when applied to biceps humeri in addition to quadriceps femoris. Additionally, to evaluate whether elements of the tool correlate with clinical measures of disease severity. METHODS: 55 patients with JDM with muscle biopsy tissue and clinical data available were included. Biopsy samples (33 quadriceps, 22 biceps) were prepared and stained using standardised protocols. A Latin square design was used by the International Juvenile Dermatomyositis Biopsy Consensus Group to score cases using our previously published score tool. Reliability was assessed by intraclass correlation coefficient (ICC) and scorer agreement (α) by assessing variation in scorers' ratings. Scores from the most reliable tool items correlated with clinical measures of disease activity at the time of biopsy. RESULTS: Inter- and intraobserver agreement was good or high for many tool items, including overall assessment of severity using a Visual Analogue Scale. The tool functioned equally well on biceps and quadriceps samples. A modified tool using the most reliable score items showed good correlation with measures of disease activity. CONCLUSIONS: The JDM biopsy score tool has high inter- and intraobserver agreement and can be used on both biceps and quadriceps muscle tissue. Importantly, the modified tool correlates well with clinical measures of disease activity. We propose that standardised assessment of muscle biopsy tissue should be considered in diagnostic investigation and clinical trials in JDM
Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study
Systemic Lupus Erythematosus (SLE) is an autoimmune, inflammatory disease that mainly affects
women. The prognosis of SLE has improved dramatically, but mortality rates are still higher than in the
general population. With the improved general prognosis, cardiovascular disease (CVD) has emerged as a
major cause of morbidity and mortality among SLE patients. Previous studies have demonstrated that the
development of atherosclerosis is accelerated in SLE, and have identified a set of traditional and nontraditional
risk factors that characterize SLE patients with CVD. Nevertheless, many unsolved issues with
respect to SLE related CVD remain. The general aim of this thesis was to investigate risk factors for
manifest CVD and for cardiovascular mortality (CVM) in SLE, with special focus on traditional risk
factors, lupus phenotype, inflammatory and endothelial biomarkers, autoantibodies and genetic
predisposition.
In the first paper, we prospectively studied traditional and non-traditional risk factors for
the development of the first cardiovascular event (CVE) in 182 SLE patients with a follow-up time of 8
years. 24(13%) patients had a first event. We demonstrated that of the traditional risk factors, only age
and smoking predicted the first CVE. Additionally, antiphospholipid antibodies (aPL), endothelial
biomarkers, represented by soluble vascular cell adhesion molecule 1(sVCAM-1), and absence of
thrombocytopenia were independent predictors of CVE. Thus, activation of the endothelium and the
coagulation system are important features in SLE-related CVD and the importance to advocate smoking
cessation among SLE patients is underscored
In the second paper, we prospectively investigated causes of mortality and risk factors for
overall mortality and CVM in a cohort of 208 SLE patients, with a follow-up time of 12 years. We also
evaluated Systematic coronary risk evaluation (SCORE, tool for evaluating the 10 year risk for
cardiovascular death in the age span 40-65 years, based on traditional risk factors) in this population.
Cystatin C, a sensitive measure of renal function, in addition to traditional and non-traditional risk
factors, were evaluated as risk factors. 42 patients died, 48 % of which were due to CVM. Age, previous
arterial events and high cystatin C levels were the strongest predictors for overall mortality and for CVM.
After adjusting for these three variables, smoking, sVCAM-1 and high sensitiviy C-reactive protein
(hsCRP) predicted CVM. SCORE estimated 4 but we observed 9 cases of CVM, a non-significant
difference. We conclude that except for smoking, traditional risk factors are less important than cystatin
C, endothelial and inflammatory biomarkers as predictors of CVM in SLE patients.
In the third paper, we investigated whether a risk allele for SLE in the signal transducer
and activator of transcription factor 4 gene (STAT4) was associated with vascular events or presence of
antiphospholipid antibodies (aPL). A total of 578 unrelated SLE patients (424 from mid-Sweden and 154
from southern-Sweden) were included in a cross-sectional design. Occurrence of previous cardiovascular
events and aPL were tabulated. Matched controls (N=651) were genotyped as a comparison. The results
demonstrate that the STAT4 risk allele was associated with ischemic cerebrovascular disease (ICVD),
with a dose-dependent relationship between ICVD and number of risk alleles. The risk allele was
furthermore associated with the presence of two or more aPLs, also in a dose-dependent manner. The
association remained after adjustment for known traditional risk factors. We conclude that patients with
the STAT4 risk allele have an increased risk of ICVD. Our results imply that genetic predisposition is an
important risk factor for ICVD in SLE patients, and that aPL may be one underlying mechanism.
In the fourth paper, we evaluated the potential association between smoking and aPL. 367
SLE patients were investigated in a cross-sectional study. Occurrence of aPL (anticardiolipin (aCL) IgG
and IgM, anti-β2 glycoprotein-1 IgG (aβ2GP1 IgG), lupus anticoagulant (LAC)) and smoking habits
(never, ever, former, current) were tabulated. Never smoking was used as reference in all calculations. In
multivariable models, adjusted for age, sex and age at disease onset, aCL and aβ2GP1 of the IgG isotype
and LAC were associated with ever smoking, this association seemed to be driven mainly by the former
smoking group. Our results demonstrate that smoking is associated with pro-thrombotic aPL in SLE
patients, though we can not from this study draw firm conclusions about the temporal relationship
between exposure to smoking and occurrence of aPL. Further studies are warranted to investigate the
mechanisms behind these observations.
In prospective studies we have demonstrated that in particular smoking, systemic
inflammation, endothelial activation and aPL are major risk factors for SLE related CVD and CVM.
Furthermore, genetic predisposition, in our studies represented by a STAT4 SLE risk allele, contributes to
the high risk of ICVD and to the occurrence of aPL, a possible underlying pathogenic mechanism. Finally
we demonstrate that smoking, known to have unfavorable effects on the immune system and to
significantly increase cardiovascular risk in SLE patients, is also associated with pro-thrombotic aPL in
patients with SLE. Thus in SLE smoking stands out as the most important of the traditional risk factors
with potential influence also on lupus related risk factors such as aPL
Autoantigenic properties of the aminoacyl tRNA synthetase family in idiopathic inflammatory myopathies
Objectives: Autoantibodies are thought to play a key role in the pathogenesis of idiopathic inflammatory myopathies (IIM). However, up to 40% of IIM patients, even those with clinical manifestations of anti-synthetase syndrome (ASSD), test seronegative to known myositis-specific autoantibodies. We hypothesized the existence of new potential autoantigens among human cytoplasmic aminoacyl tRNA synthetases (aaRS) in patients with IIM.
Methods: Plasma samples from 217 patients with IIM according to 2017 EULAR/ACR criteria, including 50 patients with ASSD, 165 without, and two with unknown ASSD status were identified retrospectively, as well as age and gender-matched sera from 156 population controls, and 219 disease controls. Patients with previously documented ASSD had to test positive for at least one of the five most common anti-aaRS autoantibodies (anti-Jo1, -PL7, -PL12, -EJ, and -OJ) and present with one or more of the following clinical manifestations: interstitial lung disease, myositis, arthritis, Raynaud's phenomenon, fever, or mechanic's hands. Demographics, laboratory, and clinical data of the IIM cohort (ASSD and non-ASSD) were compared. Samples were screened using a multiplex bead array assay for presence of autoantibodies against a panel of 117 recombinant protein variants, representing 33 myositis-related proteins, including all nineteen cytoplasmic aaRS. Prospectively collected clinical data for the IIM cohort were retrieved and compared between groups within the IIM cohort and correlated with the results of the autoantibody screening. Principal component analysis was used to analyze clinical manifestations between ASSD, non-ASSD groups, and individuals with novel anti-aaRS autoantibodies.
Results: We identified reactivity towards 16 aaRS in 72 of the 217 IIM patients. Twelve patients displayed reactivity against nine novel aaRS. The novel autoantibody specificities were detected in four previously seronegative patients for myositis-specific autoantibodies and eight with previously detected myositis-specific autoantibodies. IIM individuals with novel anti-aaRS autoantibodies (n = 12) all had signs of myositis, and they had either muscle weakness and/or muscle enzyme elevation, 2/12 had mechanic's hands, 3/12 had interstitial lung disease, and 2/12 had arthritis. The individuals with novel anti-aaRS and a pathological muscle biopsy all presented widespread up-regulation of major histocompatibility complex class I. The reactivities against novel aaRS could be confirmed in ELISA and western blot. Using the multiplex bead array assay, we could confirm previously known reactivities to four of the most common aaRS (Jo1, PL12, PL7, and EJ (n = 45)) and identified patients positive for anti-Zo, -KS, and -HA (n = 10) that were not previously tested. A low frequency of anti-aaRS autoantibodies was also detected in controls.
Conclusion: Our results suggest that most, if not all, cytoplasmic aaRS may become autoantigenic. Autoantibodies against new aaRS may be found in plasma of patients previously classified as seronegative with potential high clinical relevance.publishedVersio
Autoantibodies Produced at the Site of Tissue Damage Provide Evidence of Humoral Autoimmunity in Inclusion Body Myositis
Inclusion body myositis (IBM) belongs to a group of muscle diseases known as the inflammatory myopathies. The presence of antibody-secreting plasma cells in IBM muscle implicates the humoral immune response in this disease. However, whether the humoral immune response actively contributes to IBM pathology has not been established. We sought to investigate whether the humoral immune response in IBM both in the periphery and at the site of tissue damage was directed towards self-antigens. Peripheral autoantibodies present in IBM serum but not control serum recognized self-antigens in both muscle tissue and human-derived cell lines. To study the humoral immune response at the site of tissue damage in IBM patients, we isolated single plasma cells directly from IBM-derived muscle tissue sections and from these cells, reconstructed a series of recombinant immunoglobulins (rIgG). These rIgG, each representing a single muscle-associated plasma cell, were examined for reactivity to self-antigens. Both, flow cytometry and immunoblotting revealed that these rIgG recognized antigens expressed by cell lines and in muscle tissue homogenates. Using a mass spectrometry-based approach, Desmin, a major intermediate filament protein, expressed abundantly in muscle tissue, was identified as the target of one IBM muscle-derived rIgG. Collectively, these data support the view that IBM includes a humoral immune response in both the periphery and at the site of tissue damage that is directed towards self-antigens
The EuroMyositis registry: an international collaborative tool to facilitate myositis research
Aims: The EuroMyositis Registry facilitates collaboration across the idiopathic inflammatory myopathy (IIM) research community. This inaugural report examines pooled Registry data.
Methods: Cross-sectional analysis of IIM cases from 11 countries was performed. Associations between clinical subtypes, extramuscular involvement, environmental exposures and medications were investigated.
Results: Of 3067 IIM cases, 69% were female. The most common IIM subtype was dermatomyositis (DM) (31%). Smoking was more frequent in connective tissue disease overlap cases (45%, OR 1.44, 95% CI 1.09 to 1.90, p=0.012). Smoking was associated with interstitial lung disease (ILD) (OR 1.32, 95% CI 1.06 to 1.65, p=0.013), dysphagia (OR 1.43, 95% CI 1.16 to 1.77, p=0.001), malignancy ever (OR 1.78, 95% CI 1.36 to 2.33, p<0.001) and cardiac involvement (OR 2.40, 95% CI 1.60 to 3.60, p<0.001). Dysphagia occurred in 39% and cardiac involvement in 9%; either occurrence was associated with higher Health Assessment Questionnaire (HAQ) scores (adjusted OR 1.79, 95% CI 1.43 to 2.23, p<0.001). HAQ scores were also higher in inclusion body myositis cases (adjusted OR 3.85, 95% CI 2.52 to 5.90, p<0.001). Malignancy (ever) occurred in 13%, most commonly in DM (20%, OR 2.06, 95% CI 1.65 to 2.57, p<0.001). ILD occurred in 30%, most frequently in antisynthetase syndrome (71%, OR 10.7, 95% CI 8.6 to 13.4, p<0.001). Rash characteristics differed between adult-onset and juvenile-onset DM cases ('V' sign: 56% DM vs 16% juvenile-DM, OR 0.16, 95% CI 0.07 to 0.36, p<0.001). Glucocorticoids were used in 98% of cases, methotrexate in 71% and azathioprine in 51%.
Conclusion: This large multicentre cohort demonstrates the importance of extramuscular involvement in patients with IIM, its association with smoking and its influence on disease severity. Our findings emphasise that IIM is a multisystem inflammatory disease and will help inform prognosis and clinical management of patients
- …